These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33146298)

  • 1. Ultra-processed products industry operating as an interest group.
    Mariath AB; Martins APB
    Rev Saude Publica; 2020; 54():107. PubMed ID: 33146298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The politics of ultra-processed foods and beverages regulatory policy in upper-middle-income countries: Industry and civil society in Mexico and Brazil.
    Gómez EJ
    Glob Public Health; 2022; 17(9):1883-1901. PubMed ID: 34555297
    [No Abstract]   [Full Text] [Related]  

  • 3. Civil society participation in global public private partnerships for health.
    Storeng KT; de Bengy Puyvallée A
    Health Policy Plan; 2018 Oct; 33(8):928-936. PubMed ID: 30165606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The informal governance of public-private partnerships in UK obesity policy: Collaborating on calorie reduction or reducing effectiveness?
    Ralston R
    Soc Sci Med; 2021 Nov; 289():114451. PubMed ID: 34673355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public-private partnerships and the politics of alcohol policy in England: the Coalition Government's Public Health 'Responsibility Deal'.
    Hawkins B; McCambridge J
    BMC Public Health; 2019 Nov; 19(1):1477. PubMed ID: 31747916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "The architecture of the state was transformed in favour of the interests of companies": corporate political activity of the food industry in Colombia.
    Mialon M; Gaitan Charry DA; Cediel G; Crosbie E; Baeza Scagliusi F; Pérez Tamayo EM
    Global Health; 2020 Oct; 16(1):97. PubMed ID: 33046110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure.
    Buse K; Tanaka S; Hawkes S
    Global Health; 2017 Jun; 13(1):34. PubMed ID: 28619031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fifty shades of partnerships: a governance typology for public private engagement in the nutrition sector.
    Patay D; Ralston R; Palu A; Jones A; Webster J; Buse K
    Global Health; 2023 Feb; 19(1):11. PubMed ID: 36804923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Big food and the World Health Organization: a qualitative study of industry attempts to influence global-level non-communicable disease policy.
    Lauber K; Rutter H; Gilmore AB
    BMJ Glob Health; 2021 Jun; 6(6):. PubMed ID: 34117011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corporate power and the international trade regime preventing progressive policy action on non-communicable diseases: a realist review.
    Milsom P; Smith R; Baker P; Walls H
    Health Policy Plan; 2021 May; 36(4):493-508. PubMed ID: 33276385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of food industry strategies to influence public health policy, research and practice in South Africa.
    Mialon M; Crosbie E; Sacks G
    Int J Public Health; 2020 Sep; 65(7):1027-1036. PubMed ID: 32728853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Legal Feasibility of US Government Policies to Reduce Cancer Risk by Reducing Intake of Processed Meat.
    Wilde P; Pomeranz JL; Lizewski LJ; Ruan M; Mozaffarian D; Zhang FF
    Milbank Q; 2019 Jun; 97(2):420-448. PubMed ID: 31016816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corporate interest groups and their implications for global food governance: mapping and analysing the global corporate influence network of the transnational ultra-processed food industry.
    Slater S; Lawrence M; Wood B; Serodio P; Baker P
    Global Health; 2024 Feb; 20(1):16. PubMed ID: 38388413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public opinion about evidence-informed health policy development in U.S. Congress.
    Purtle J
    Transl Behav Med; 2020 Dec; 10(6):1549-1553. PubMed ID: 31209499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy.
    Ulucanlar S; Lauber K; Fabbri A; Hawkins B; Mialon M; Hancock L; Tangcharoensathien V; Gilmore AB
    Int J Health Policy Manag; 2023; 12():7292. PubMed ID: 37579378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coca-Cola's political and policy influence in Mexico: understanding the role of institutions, interests and divided society.
    Gómez EJ
    Health Policy Plan; 2019 Sep; 34(7):520-528. PubMed ID: 31381805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugar and health in South Africa: Potential challenges to leveraging policy change.
    Myers A; Fig D; Tugendhaft A; Mandle J; Myers J; Hofman K
    Glob Public Health; 2017 Jan; 12(1):98-115. PubMed ID: 26315455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engaging with the Private Sector for Noncommunicable Disease Prevention and Control: Is it Possible to Create "Shared Value?".
    Collins TE; Akselrod S; Mahy L; Poznyak V; Berlina D; Hatefi A; Allen L
    Ann Glob Health; 2023; 89(1):46. PubMed ID: 37425141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity agenda in Brazil, conflicts of interest and corporate activity.
    Burlandy L; Prado Alexandre-Weiss V; Silva Canella D; Feldenheimer da Silva AC; Maranha Paes de Carvalho C; Rugani Ribeiro de Castro I
    Health Promot Int; 2021 Aug; 36(4):1186-1197. PubMed ID: 33169128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Political strategy 101: how to make health policy and influence political people.
    Mebane F; Blendon RJ
    J Child Neurol; 2001 Jul; 16(7):513-9. PubMed ID: 11453449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.